The investment builds on a collaboration the companies entered into in 2007 for various biomanufacturing projects.
On Nov. 29, 2018, Tosoh Bioscience, a provider of liquid chromatography products, announced that it has completed an equity investment in Semba Biosciences, a US-based provider of instruments, reagents, and methods for purification of biomolecules and chemicals, with the intention of acquiring full ownership of the company. Tosoh Bioscience is a US-based subsidiary of Tosoh Corporation in Japan.
The transaction was approved by both companies’ boards of directors. “Our respective technologies fit perfectly together to provide an integrated solution for bioprocess research, development, and continuous manufacturing,” said Dr. Robert Mierendorf, president of Semba Biosciences, in a company press release.
The two companies have been collaborating on various downstream biomanufacturing projects since 2007, combining Semba Biosciences’ advanced simulated moving bed (SMB) technology with Tosoh Bioscience’s resins.
Source: Tosoh Bioscience
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.